drugset / Trial / NCT00928525
Imatinib in Patients With Desmoid Tumor and Chondrosarcoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether Imatinib Mesylate is active in diseases - such as Desmoid Tumor and Chondrosarcoma - expressing the receptor for the platelet-derived growth factor (PDGF) both in its isoform alpha and beta
Timeline
- Start
- 2007-05
- Primary completion
- 2018-12
- Completion
- 2018-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imatinib | Small molecule | 400 mg | Oral |